

Attorney Docket No.: ISPH-0614  
Inventors: Wu et al.  
Serial No.: 09/992,738  
Filing Date: November 14, 2001  
Page 5

The following listing of claims will replace all prior versions and listings of claims in this application.

**Listing of Claims:**

Claim 1 (original): A human RNase H1 polypeptide which comprises one or more mutations compared to wild type human RNase H1, wherein said mutation produces a mutant version of human RNase H1 polypeptide that consists of a deletion mutation of at least a portion of region I, a deletion mutation of at least a portion of region II, a deletion mutation of at least a portion of region I and region II, or a lysine-to-alanine substitution at amino acids 226 and 227 of SEQ ID NO: 1, and wherein said mutant version retains detectable cleavage activity for the RNA strand of an RNA/DNA duplex.

Claims 2-9 (canceled).

Claim 10 (original): A composition comprising the human RNase H1 polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Claim 11 (currently amended): A human H1 polypeptide which consists solely of the basic substrate binding domain which consists of ~~(region III)~~ and which retains detectable cleavage activity for the RNA strand of an RNA/DNA duplex.

Attorney Docket No.: ISPH-0614  
Inventors: Wu et al.  
Serial No.: 09/992,738  
Filing Date: November 14, 2001  
Page 6

Claim 12 (original): The RNase H1 polypeptide of claim 11 which has an initial cleavage rate for the RNA strand of an RNA/DNA duplex which is at least 50% of the initial cleavage rate for a wild type human RNase H1.

Claim 13 (original): A composition comprising the human RNase H1 polypeptide of claim 11 and a pharmaceutically acceptable carrier.

Claims 14-42 (canceled).